Bailard’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.4M Buy
6,016
+335
+6% +$77.4K 0.03% 294
2026
Q2
$1.2M Buy
5,681
+136
+2% +$26.7K 0.02% 319
2026
Q1
$1.09M Buy
5,545
+1,499
+37% +$291K 0.03% 313
2025
Q4
$702K Buy
+4,046
New +$737K 0.02% 401
2021
Q2
– Sell
-2,668
Closed -$342K – 716
2021
Q1
$342K Sell
2,668
-37,868
-93% -$4.67M 0.01% 472
2020
Q4
$4.83M Buy
40,536
+378
+0.9% +$46.1K 0.22% 93
2020
Q3
$4.6M Buy
40,158
+867
+2% +$102K 0.24% 84
2020
Q2
$4.48M Buy
39,291
+3,995
+11% +$424K 0.25% 83
2020
Q1
$2.83M Buy
35,296
+5,502
+18% +$570K 0.2% 100
2019
Q4
$3.18M Buy
29,794
+7,520
+34% +$784K 0.18% 114
2019
Q3
$2.38M Buy
22,274
+1,709
+8% +$175K 0.14% 139
2019
Q2
$2.09M Buy
20,565
+882
+4% +$84.8K 0.13% 155
2019
Q1
$1.77M Sell
19,683
-68
-0.3% -$5.89K 0.11% 165
2018
Q4
$1.64M Sell
19,751
-14,664
-43% -$1.37M 0.11% 162
2018
Q3
$3.71M Sell
34,415
-476
-1% -$52.2K 0.22% 101
2018
Q2
$3.84M Buy
+34,891
New +$3.63M 0.23% 99

Other funds holding DGX

Bailard's DGX Position: Q3 2026 in Review

Bailard increased its Quest Diagnostics (DGX) stake by 5.9% in Q3 2026, buying an estimated $77.4K and bringing the position to 6,016 shares worth $1.4M. The position accounts for 0.03% of the portfolio, ranked #294.

Bailard first reported a position in DGX in Q2 2018 and has held it in 16 quarters since. The position peaked at $4.83M in Q4 2020. 192 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Bailard held 6,016 shares of Quest Diagnostics worth $1.4M as of Q3 2026.
  • Bailard bought 335 Quest Diagnostics shares in Q3 2026, an estimated $77.4K.
  • Quest Diagnostics made up 0.03% of Bailard's portfolio in Q3 2026, its #294 holding.
  • Bailard first reported a position in Quest Diagnostics in Q2 2018 and has held it in 16 quarters since.
  • Bailard's Quest Diagnostics position peaked at $4.83M in Q4 2020.
  • 192 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.